Stockholm, Sweden Saturday, February 22, 2025, 09:00 Hrs [IST] ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

While Health Technology Assessment agencies anticipate that joint efforts and harmonisation will enhance evaluations’ efficiency, tangible evidence is taking time to materialise.

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

The Canadian dollar is plunging against the Swiss franc during trading on Thursday, as the 200-day EMA has shown itself to be ...

EUR/USD slumps to near 1.0470 after the release of February's preliminary PMI data for the Eurozone and its major nations.